Successful use of infliximab therapy in sight-threatening corticosteroid-resistant Vogt-Koyanagi-Harada disease

Ocular Immunology and Inflammation

Volumn 21, Issue 4, 2013, Pages 310-316

  Zmuda, Mathieu ^a   Tiev, Kiet Phong ^b   Knoeri, Juliette ^a   Héron, Emmanuel ^a  

^a CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

Infliximab; Therapy; Tuberculosis; Uveitis; Vogt Koyanagi Harada

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; INFLIXIMAB; ISONIAZID PLUS RIFAMPICIN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLURRED VISION; CASE REPORT; CEREBROSPINAL FLUID; CHOLESTASIS; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DRUG MEGADOSE; DRUG PULSE THERAPY; EYE EXAMINATION; FEMALE; GRANULOMATOSIS; HAND MOVEMENT; HEADACHE; HUMAN; LUMBAR PUNCTURE; MALAISE; MEDICAL RECORD REVIEW; MOVEMENT PERCEPTION; MULTIVISCERAL TUBERCULOSIS; NAUSEA; OPTICAL COHERENCE TOMOGRAPHY; PAPILLITIS; PLEOCYTOSIS; RETINA DETACHMENT; RETINA FOVEA; RIGIDITY; TINNITUS; TUBERCULOSIS; VISUAL ACUITY; VOGT KOYANAGI SYNDROME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; MIDDLE AGED; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UVEOMENINGOENCEPHALITIC SYNDROME; VISUAL ACUITY; YOUNG ADULT;

EID: 84879775309     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2013.775312     Document Type: Article

References (13)

1. Bordaberry MF. Vogt-Koyanagi-Harada disease: Diagnosis and treatment update. Curr Opin Ophthalmol. 2010;21: 430-435
2. Rao NA, Gupta A, Dustin L, et al. Frequency of distinguishing clinical features in Vogt-Koyanagi-Harada disease. Ophthalmology 2010;117:591-599
3. Ohno S, Minakawa R, Matsuda H. Clinical studies of Vogt-Koyanagi-Harada's disease. Jpn J Ophthalmol. 1988;32: 334-343
4. Chee SP, Jap A, Bacsal K. Prognostic factors of Vogt-Koyanagi-Harada disease in Singapore. Am J Ophthalmol. 2009;147:154-161
5. Wang Y, Gaudio PA. Infliximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome. Ocul Immunol Inflamm. 2008;16:167-171
6. Niccoli L, Nannini C, Cassara E, et al. Efficacy of infliximab therapy in two patients with refractory Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 2009;93: 1553-1554
7. Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: Report of an international committee on nomenclature. Am J Ophthalmol. 2001;131:647-652
8. Yamanaka E, Ohguro N, Yamamoto S, et al. Evaluation of pulse corticosteroid therapy for Vogt-Koyanagi-Harada disease assessed by optical coherence tomography. Am J Ophthalmol. 2002;134:454-456
9. Liu L, Yang P, He H, et al. Leptin increases in Vogt-Koyanagi-Harada (VKH) disease and promotes cell proliferation and inflammatory cytine secretion. Br J Ophthalmol. 2008;92: 557-561
10. Sugita S, Yamada Y, Kaneko S, et al. Induction of regulatory T cells by infliximab in Behçet's disease. Invest Ophthalmol Vis Sci. 2011;52:476-484
11. Chen L, Yang P, Zhou H, et al. Diminished frequency and function of CD4 CD25 high regulatory T cells associated with active uveitis in Vogt-Koyanagi-Harada syndrome. Invest Ophthalmol Vis Sci. 2008;49:3475-3482
12. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumor necrosis factor antagonist therapies: A TBNETconsensus statement. Eur Respir J. 2010; 36:925-949
13. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The threeyear prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009; 60:1884-1894